Clinical experience with superior vena caval Greenfield filters.

E Ascher, A Hingorani, F Mazzariol, T Jacob, W Yorkovich, P Gade
{"title":"Clinical experience with superior vena caval Greenfield filters.","authors":"E Ascher,&nbsp;A Hingorani,&nbsp;F Mazzariol,&nbsp;T Jacob,&nbsp;W Yorkovich,&nbsp;P Gade","doi":"10.1583/1074-6218(1999)006<0365:CEWSVC>2.0.CO;2","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the results of superior vena caval (SVC) Greenfield filters in patients at risk for pulmonary embolism (PE) secondary to upper extremity deep venous thrombosis (UEDVT).</p><p><strong>Methods: </strong>Over a 46-month period, 26 patients (10 men, mean age 67 years, range 25 to 89) with UEDVT in whom anticoagulation was contraindicated (n = 22) or ineffective in preventing recurrent PE or extension of the thrombus (n = 4) were treated with placement of SVC Greenfield filters.</p><p><strong>Results: </strong>One SVC filter was misplaced into the innominate vein but left in place; this vein remains patent after 2 months without evidence of filter migration. Follow-up ranged from 10 days to 46 months (mean 7.8 months). Fifteen (58%) patients died inhospital of causes unrelated to the SVC filter or recurrent thromboembolism (mean time to death 36 days). Of the 11 survivors, follow-up ranged from 1 to 38 months (mean 22). Sequential chest roentgenograms in 9 (82%) patients revealed no filter migration or displacement. No evidence of PE was found in any of the survivors over the course of follow-up.</p><p><strong>Conclusions: </strong>Insertion of SVC Greenfield filters is a safe and feasible therapy to prevent recurrent thromboembolism in patients with UEDVT who are refractory to or inappropriate for anticoagulation therapy.</p>","PeriodicalId":79443,"journal":{"name":"Journal of endovascular surgery : the official journal of the International Society for Endovascular Surgery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1999-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of endovascular surgery : the official journal of the International Society for Endovascular Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1583/1074-6218(1999)006<0365:CEWSVC>2.0.CO;2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 22

Abstract

Purpose: To evaluate the results of superior vena caval (SVC) Greenfield filters in patients at risk for pulmonary embolism (PE) secondary to upper extremity deep venous thrombosis (UEDVT).

Methods: Over a 46-month period, 26 patients (10 men, mean age 67 years, range 25 to 89) with UEDVT in whom anticoagulation was contraindicated (n = 22) or ineffective in preventing recurrent PE or extension of the thrombus (n = 4) were treated with placement of SVC Greenfield filters.

Results: One SVC filter was misplaced into the innominate vein but left in place; this vein remains patent after 2 months without evidence of filter migration. Follow-up ranged from 10 days to 46 months (mean 7.8 months). Fifteen (58%) patients died inhospital of causes unrelated to the SVC filter or recurrent thromboembolism (mean time to death 36 days). Of the 11 survivors, follow-up ranged from 1 to 38 months (mean 22). Sequential chest roentgenograms in 9 (82%) patients revealed no filter migration or displacement. No evidence of PE was found in any of the survivors over the course of follow-up.

Conclusions: Insertion of SVC Greenfield filters is a safe and feasible therapy to prevent recurrent thromboembolism in patients with UEDVT who are refractory to or inappropriate for anticoagulation therapy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
上腔静脉格林菲尔德过滤器的临床应用体会。
目的:评价上腔静脉(SVC) Greenfield过滤器在上肢深静脉血栓(UEDVT)继发肺栓塞(PE)风险患者中的效果。方法:在46个月的时间里,26例UEDVT患者(10名男性,平均年龄67岁,范围25至89岁),抗凝治疗禁忌(n = 22)或对预防PE复发或血栓扩展无效(n = 4),放置SVC Greenfield过滤器进行治疗。结果:1个SVC滤光片错位进入无名静脉,但仍留在原位;2个月后静脉通畅,无滤过物迁移。随访10天至46个月(平均7.8个月)。15例(58%)患者死于与SVC滤过器无关的原因或复发性血栓栓塞(平均死亡时间36天)。在11名幸存者中,随访时间为1至38个月(平均22个月)。9例(82%)患者的序贯胸片显示没有滤过膜迁移或移位。在随访过程中,没有发现任何幸存者有PE的证据。结论:对于抗凝治疗难治性或不适合抗凝治疗的UEDVT患者,植入SVC Greenfield滤过器是一种安全可行的预防血栓复发的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Aorto-left renal vein fistula: is there a place for endovascular management? Aortocaval fistula: a challenge for endovascular management. Endovascular repair of an aortoenteric fistula in a high-risk patient. Carotid stenting using radial artery access. Neurological monitoring during carotid artery stenting: the Duck Squeezing Test.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1